Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston.
School of Medicine, University of California-San Diego.
JAMA Surg. 2015 Dec;150(12):1160-6. doi: 10.1001/jamasurg.2015.2644.
To our knowledge, long-term outcomes of open and endovascular (EVAR) repairs of abdominal aortic aneurysms (AAAs) have not been studied on a population level outside a controlled trial setting.
To determine long-term outcomes of EVAR vs open repair on a population level.
DESIGN, SETTING, AND PARTICIPANTS: Analysis of the longitudinally linked California Office of Statewide Health Planning and Development inpatient database from 2001 to 2009. Median follow-up was 3.3 years.
Endovascular vs open repairs.
Mortality and complications at 30 days, as well as long-term mortality and complications up to 9 years.
In this observational study, a total of 23 670 patients were studied, with 52% receiving EVAR. Endovascular repair was associated with improved 30-day outcomes (all-cause mortality, readmission, surgical site infection, pneumonia, and sepsis), as well as significantly improved survival until 3 years postoperatively. After 3 years, mortality was higher for patients who underwent an EVAR repair. No significant difference in long-term mortality was observed for the entire cohort on adjusted analysis (hazard ratio, 0.99; 95% CI, 0.94-1.04; P = .64). Endovascular repair was found to be associated with a significantly higher rate of reinterventions and AAA late ruptures.
The survival advantage for EVAR repair in a statewide population is maintained for 3 years. After 3 years, EVAR repair was associated with higher mortality; however, these mortality differences did not reach statistical significance over the entire study period. Reintervention and late AAA rupture rates are higher after EVAR repair.
据我们所知,在临床试验环境之外,尚未在人群水平上研究开放和血管内(EVAR)修复腹主动脉瘤(AAA)的长期结果。
确定人群水平上 EVAR 与开放修复的长期结果。
设计、设置和参与者:对 2001 年至 2009 年期间纵向链接的加利福尼亚州全州卫生规划和发展办公室住院患者数据库进行分析。中位随访时间为 3.3 年。
血管内与开放修复。
30 天内的死亡率和并发症,以及长达 9 年的长期死亡率和并发症。
在这项观察性研究中,共研究了 23670 名患者,其中 52%接受了 EVAR 治疗。血管内修复与 30 天内结局改善相关(全因死亡率、再入院、手术部位感染、肺炎和败血症),并且术后 3 年内的生存率显著提高。3 年后,接受 EVAR 修复的患者死亡率更高。在调整分析中,整个队列的长期死亡率无显著差异(风险比,0.99;95%CI,0.94-1.04;P = .64)。血管内修复与再干预和 AAA 晚期破裂的发生率显著增加相关。
在全州人群中,EVAR 修复的生存优势可维持 3 年。3 年后,EVAR 修复与更高的死亡率相关;然而,在整个研究期间,这些死亡率差异并未达到统计学意义。EVAR 修复后再干预和晚期 AAA 破裂的发生率更高。